1. Novartis (protocol ASM981C2315) A 26-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when pimecrolimus cream 1% is used at the first signs and/or symptoms of atopic dermatitis and its safety and tolerability in children and adolescents 2-17 years of age www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp (accessed 1st August 2006) 2005
2. Novartis (protocol ASM981C2316) A 26-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when pimecrolimus cream 1% is used at the first signs and/or symptoms of atopic dermatitis and its safety and tolerability in adults 18 years of age and older www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp (accessed 1st August 2006) 2005
3. Novartis (protocol ASM981C2402) An exploratory, randomized, double-blind, vehicle-controlled, multicenter, parallel dose study investigating the use of pimecrolimus cream 1% in mild to moderate atopic dermatitis patients who demonstrate a clinical insensitivity to topical glucocorticoids www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp (accessed 1st August 2006) 2005
4. Novartis (protocol ASM981CDE10) A 24-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study on pimecrolimus cream 1% assessing the steroid-sparing effect in the long term management of pediatric patients with severe atopic dermatitis www.novartisclinicaltrials.com/clinicaltrialrepository/public/login.jsp?target=%2Fclinicaltrialrepository%2Fpublic%2Fmain.jsp (accessed 1st August 2006) 2005
5. Barba JF Beirana A Cohen V Dominguez L Duran C Leon G Pimecrolimus cream 1% is effective, well tolerated and safe in infants and children with atopic eczema of the face Journal of the European Academy of Dermatology and Venereology 2003 P2.35